Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

VANCOUVER, British Columbia & GRAPEVINE, Texas, February 25, 2026--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company"), a clinical-stage biopharmaceutical company ...

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens

VANCOUVER, British Columbia & GRAPEVINE, Texas, February 18, 2026--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company"), a biopharmaceutical company focused on developing ...
Nasdaq

Alpha Cognition Announces Voluntary Delisting from CSE

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, or the “Company”), announces that in connection with the Company’s listing on the Nasdaq ...
Morningstar

Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced ...
Seeking Alpha

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating ...
AOL

Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China

On Wednesday, Alpha Cognition Inc. (NASDAQ:ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for the development, manufacturing, and commercialization of ...
Morningstar

Alpha Cognition Announces Partial Exercise of Over-allotment Option

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and ...
Business Insider

Alpha Cognition commercially launches ZUNVEYL to treat mild to moderate AD

Alpha Cognition (ACOG) announced the official commercial launch of ZUNVEYL, a new treatment for mild to moderate Alzheimer’s disease. This milestone marks a major step forward in the company’s mission ...
Nasdaq

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies ...
Business Wire

Alpha Cognition Announces $6.8 Million Private Placement

VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel ...
Business Wire

Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and ...
Seeking Alpha

Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating ...